One major problem with the use of SAA, an acute-phase reactant, as a potential serum marker in human cancer patients, is the fact that its elevation in the serum of patients is suggested to be of liver origin rather than a tumour–cell product (Diamandis, 2004). This evidence concerns the gene SAA1 and neoplasm.